John V Oyler, Founder, Chairman and CEO at BeOne Medicines, shared BeOne Medicines‘s post o LinkedIn, adding:
“News for Investors and Media:
Proud to share BeOne’s Q3 2025 results — another milestone on our path to becoming the world’s leading oncology company.
- This quarter, we delivered 41% revenue growth to $1.4B and achieved strong momentum across our portfolio
- BRUKINSA reached $1.0B in global revenue, now the global leader in the BTK inhibitor class.
- Earnings per ADS: GAAP $1.09 | Non-GAAP $2.65
- Continued progress with sonrotoclax and our degrader, BGB-16673, reinforcing our leadership in B-cell malignancies.
Nearly 50 BeOne abstracts were accepted for presentation at the upcoming ASH 2025 Annual Meeting, reflecting our deep scientific strength and commitment to delivering the best long-term outcomes for patients.
Thank you to our patients, their families, clinicians, and our 12,000 colleagues across six continents.
Together, we are how the world stops cancer – and we’re just getting started.”
Quoting BeOne Medicines‘s post:
“News for Investors and Media:
BeOne Medicines announces third quarter 2025 financial results and business updates.
Read the full press release here.”
Proceed to the video attached to the post.
More posts featuring John V Oyler.